Title: Actimid (Celgene)
CAS Registry Number: 19171-19-8
CAS Name: 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
Additional Names: 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Manufacturers' Codes: CC-4047
Molecular Formula: C13H11N3O4
Molecular Weight: 273.24
Percent Composition: C 57.14%, H 4.06%, N 15.38%, O 23.42%
Literature References: Second generation immunomodulator and TNF-a inhibitor; analog of thalidomide, q.v. Prepn: G. W. Muller et al., WO 9803502; eidem, US 6335349 (1998, 2002 both to Celgene); eidem, Bioorg. Med. Chem. Lett. 9, 1625 (1999). In vivo immunostimulant activity in cancer vaccine model: K. Dredge et al., J. Immunol. 168, 4914 (2002). Mechanism of action study: F. Payvandi et al., Cell. Immunol. 230, 81 (2004). In vitro immunodulation of hematopoietic stem cells: K.-R. Koh et al., Blood 105, 3833 (2005). Clinical pharmacokinetics and clinical evaluation in multiple myeloma: S. A. Schey et al., J. Clin. Oncol. 22, 3269 (2004).
Properties: Yellow solid from dioxane + ethyl acetate, mp 318.5 - 320.5°.
Melting point: mp 318.5 - 320.5°
Therap-Cat: Immunomodulator.
Keywords: Immunomodulator.
Actinobolin Actinodaphnine Actinomycetin Actinomycin F1 Actinoquinol

Systematic (IUPAC) name
Clinical data
Trade names Imnovid, Pomalyst
Licence data EMA:Link, US FDA:link
Pregnancy cat. X (US)
Legal status POM (UK) -only (US)
Routes Oral
Pharmacokinetic data
Protein binding 12-44%
Metabolism Hepatic (mostly CYP1A2 and CYP3A4 mediated; some minor contributions by CYP2C19 and CYP2D6)
Half-life 7.5 hours
Excretion Urine (73%), faeces (15%)
CAS number 19171-19-8 YesY
ATC code L04AX06
PubChem CID 134780
ChemSpider 118785 N
Chemical data
Formula C13H11N3O4 
Mol. mass 273.24 g/mol
 N (what is this?)  (verify)

Pomalidomide (INN, originally CC-4047 or 3-amino-thalidomide, trade name Pomalyst[1] in the US) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.[2] It received a similar approval from the European Commission in August 2013, and is expected to be marketed in Europe under the brand name Imnovid.[3]